Fig. 7

Overexpression of LINC00909 markedly increases tumor burden and promotes spleen metastasis in pancreatic ductal adenocarcinoma (PDAC). (A, B) Overall appearance of the subcutaneous xenograft models in the Vector and LINC00909-OE groups (n = 5 per group). (C) Tumor volume curves of the subcutaneous xenografts in the PANC-1/Vector and PANC-1/LINC00909-OE groups (n = 5). Tumor volume was measured once every 10 days. (D) Tumor weights (n = 5). (E) Representative appearance of orthotopic xenograft models in the Vector and LINC00909-OE groups (red arrow: orthotopic pancreatic tumor; blue arrow: metastasis in the spleen). (F) The spleen metastasis amount in the orthotopic xenograft model was computed for the indicated group (n = 6 per group). (G) Pie chart revealing the percentage of mice with spleen metastasis in these two groups. (H) H&E staining of the spleen section. (I) IHC staining of SMAD4, KLF4, c-Myc, and c-JUN in orthotopic pancreatic tumors obtained from the control and LINC00909-OE groups. All *P < 0.05; **P < 0.01. P-values were assessed using ANOVA and two-tailed t-tests, followed by Dunnett’s tests for multiple comparisons in (C, D, and F)